The Austin sports medicine doctors at Medicine in Motion have compiled a list of commonly-made mistakes by runners on the day of their race.

Austin, Texas (PRWEB) April 11, 2013

1. New clothing. Whether it's shoes, socks or any piece of apparel, race day isn't the time to try out a new article of clothing. If a runner hasn't broken it in over at least a couple of runs, don't even consider putting it on.

2. Skipping breakfast. Many first-time marathoners have pre-race jitters and, therefore, not much of an appetite. But it's important to not supplement the morning meal with just coffee or a sports drink. Eat a high-carbohydrate breakfast so the body will have enough fuel to make it to the finish line.

3. Overdressing. Since races typically start in the morning hours when it's cooler, runners often dress more warmly than necessary. It's important to remember that once the race begins, body temperatures will rise, so it will feel at least 10 degrees warmer than the actual temperature. Extra clothing leads to sweating and dehydration, and can be generally uncomfortable.

4. New foods. Just like with new clothes, before or during the race is not the time to try out different foods. Stick to the familiar, preferably foods that were eaten while practicing for the event. Even if a racer is used to a certain type of food, if they haven't previously run on it, it may have an adverse affect on their performance.

5. Warm-up extremes. When it comes to getting the body prepared just before the race, runners often make one of two types of mistakes: skipping the warm-up completely or warming-up for too long. While it makes sense to conserve as much energy as possible for the actual race, it's important to loosen up the muscles used in running. Keep the warm-up short, but don't leave it out of the pre-run routine.

6. Starting out too fast. Every runner knows the importance of keeping a steady pace during marathons. It's hard to fight the urge to bolt off the starting line, especially when others appear to be doing so. But even-pace running will ensure a racer will go strong and have the endurance to pass the quick-starters later in the race.

7. Failure to hydrate. For long-distance runners, every ounce of water consumed helps maintain the blood flow to the skin, heart and muscles. Liquids help keep body temperatures down, which is essential during a marathon. Running for an extended time slows the absorption of fluids by the body, so consuming liquids should begin early.

Medicine in Motion (MIM) specializes in providing top quality sports medicine in Austin, Texas, for athletic individuals of all ages and levels. The doctors at MIM believe active bodies are healthy bodies, therefore it is the office's goal to keep patients energetic and fit. To that end, MIM provides treatment of injuries and illnesses, including the use of physical rehabilitation; promotes healthy living with personal training and nutrition coaching; and offers comprehensive sports medicine evaluations to optimize health, activity level and sports performance. For more information or for questions regarding sports medicine in Austin, contact Medicine in Motion at 512-257-2500 or visit the website at http://www.medinmotion.com.

Original post:

Seven Common Race-Day Mistakes Made by Runners from Medicine in Motion

Newswise David Fleming, MD, chair of the Department of Internal Medicine and director of the Center for Health Ethics at the University of Missouri School of Medicine, will be named president-elect of the American College of Physicians (ACP) the largest medical specialty organization in the United States. Fleming's one-year term as president-elect begins during ACP's annual scientific meeting in San Francisco, which starts April 11. He will then serve as president of ACP from 2014 to 2015, the centennial year for the organization that was founded in 1915.

ACP is a national and international professional organization of internists physicians who specialize in the prevention, detection and treatment of illnesses in adults. Its membership of 133,000 includes internists, internal medicine subspecialists, medical students, residents and fellows.

"I am deeply honored to serve ACP and medicine in this capacity," Fleming said. "These are challenging times with the rapid and historic changes now taking place in our country's health care environment. It will be critically important that all of us be mindful of these challenges. It is also important that organizations like ACP continue to take a leading role in helping to shape the inevitable change to come in a positive and constructive way. I look forward to the challenge."

Fleming is a professor of medicine, and he has been director of the MU Center for Health Ethics since its inception in 2001. He established the center after completing a research fellowship in primary care and clinical bioethics at the Center for Clinical Bioethics at Georgetown University. MU's center has since developed a prominent state and national presence for improving the health of the public through patient-centered programs related to ethics and professionalism in education, research, clinical service and organizational performance.

Fleming has been a member of ACP since 1980 and a Fellow of the American College of Physicians since 1986. He served on ACP's Ethics and Human Rights Committee for many years, most recently as chair from 2012 to 2013, and as vice chair for ACP's Health and Public Policy Committee. He was governor for the ACP Missouri chapter from 2007 to 2011, and chair of ACP's board of governors from 2011 to 2012. While serving as its governor, the Missouri chapter received the John Tooker Evergreen Award for member outreach in 2009. Fleming also received the Laureate Award for outstanding service to medicine and to ACP from the Missouri chapter in 2012. He was a regent for ACP from 2012 to 2013.

In addition to his service through ACP, Fleming is a member of the Boone County Medical Society, American Medical Association, Association of Professors of Medicine, Southern Society of Clinical Investigators and Southern Medical Society.

Fleming graduated from medical school, completed residency in internal medicine and ultimately served as chief resident in internal medicine at MU. Following training, he returned to his hometown of Moberly, Mo., where he practiced general internal medicine and geriatrics, and was medical director of Woodland Internists Group, a multispecialty community-based clinic. While in practice, he also served on MU's clinical faculty. Fleming also established and was medical director of the Woodrail Internal Medicine Clinic in Columbia, Mo.

Fleming has received numerous awards for teaching and service, including the Distinguished Service Award from the MU Medical Alumni Organization, the Jane Hickman Teaching Award, the Robert N. McCallum Student Advocacy Award, and Faculty Member of the Year in the Department of Health Management and Informatics at the University of Missouri School of Medicine. Additionally, he was named Prince Charitable Scholar in End of Life Care at Georgetown University in 2000 and Service Excellence Hero in 2009 from MU's University Hospital.

Fleming's publication credits include authoring and co-authoring more than 60 peer reviewed journal publications and book chapters. He is also editor and author of the book "Care of the Dying Patient." He has also been invited to give numerous regional, national and international presentations.

Original post:

MU Internal Medicine Chair to Lead Largest Medical Specialty Group in U.S.

The nuclear medicine market has been forecast to increase at a compound annual growth rate (CAGR) of 7.8% over the next five years, rising from a valuation of $3.8 billion in 2012, to hit a market value of $5.5 billion by the year 2017.

The medical device industry has witnessed explosive growth in recent years. According to estimates, the global market was worth $236.1bn in 2010. Much of this growth is linked to the rising prevalence of a number of diseases worldwide; most notably in cardiac and neurological systems.

This has fuelled a strong demand for technically advanced medical and diagnostic imaging devices, capable of providing accurate and detailed diagnoses, which can allow earlier, and potentially life-saving, medical intervention.

Despite a decline in sales volume and reduced demand in the aftermath of the global economic recession, the industry has "recovered well."

Nuclear medicine is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of disease.

In nuclear medicine procedures, radionuclides are combined with other elements to form chemical compounds, or else combined with existing pharmaceutical compounds, to form radiopharmaceuticals.

These radiopharmaceuticals, once administered to the patient, can localize to specific organs or cellular receptors. This property of radiopharmaceuticals allows nuclear medicine the ability to image the extent of a disease process in the body, based on the cellular function and physiology, rather than relying on physical changes in the tissue anatomy.

In some diseases nuclear medicine studies can identify medical problems at an earlier stage than other diagnostic tests. Nuclear medicine, in a sense, is "radiology done inside out" or "endo-radiology" because it records radiation emitting from within the body rather than radiation that is generated by external sources like X-rays.

Research also suggests that the world nuclear medicine market may benefit from globalisation. Developed nuclear medicine markets such as the US and UK are highly saturated and the focus is likely to be towards upgrading stand-alone PET and SPECT system with fully integrated hybrid units, that offer a high level of anatomical and functional detail.

Emerging countries such as China and India will offer more opportunity, due a lack of nuclear medicine facilities and technologies, and increased healthcare spending. It has been predicted that healthcare investment in these countries is expected to double in the next seven years.

View post:

Nuclear medicine market to be worth $5.5 billion by 2017

NEW YORK--(BUSINESS WIRE)--

Since its inception in 2011, the African Society of Laboratory Medicine (ASLM) has focused on building capacity in African healthcare laboratories, recognizing that providing efficient and accurate diagnostic services is critical to patient health. To this end, the ASLM has leapfrogged over many of the traditional barriers to entry for adoption of medical technology, enabling medical labs in Africa to benefit from state-of-the-art software solutions that power some of the largest laboratories in America. These efforts complement the full palette of ASLMs offerings to Africas labs, including harmonization and training on quality standards, provision of reference materials, and other areas of resource mobilization.

Working in conjunction with the CDC, Clinton Health Access Initiative, UNAIDS, and WHO/AFRO, the ASLM have now partnered with SoftTech Health, in a program to network the laboratories continent-wide with the LabQMS (Quality Management Software).

The first site for the new partnership was the KEMRI/CDC HIVR lab in Kenya. The SoftTech system is transforming the Kenya Medical Research Institute/CDC HIV Research laboratory into a paperless, efficiency driven organization and makes critical information available instantly. The user friendliness and ease of access of all critical SOPs and publications, including creation and recording of information (online forms), performing audits, and generating automated tasks with reminders is saving an enormous amount of time. Adoption of this system will enable other medical laboratories across Africa to pursue internationally recognized accreditation, says Dr. Clement Zeh, Director of the KEMRI/CDC HIVR lab.

By skipping right over the traditional processes of establishing physical infrastructural technologies, and going directly to wireless and cloud-based technologies instead, were helping labs in Africa go straight to the front of the line in terms of being able to use the same software tools that the top labs in America use, says Craig Madison, Senior Partner of SoftTech Health, This program is Proof of Concept that intelligently and selectively deploying the right technologies does indeed pay real dividends, and weve seen the laboratory sites in Kenya very readily transitioning to using software to improve quality and efficiency.

Part of a global evolution in clinical laboratories, the projects labs are optimizing their services by automating their administrative processes, transitioning away from a pen-and-paper system to using software in its place. In the clinical laboratory field, a formal Quality Management System is considered an essential administrative tool, being the first line of defense in prevention of errors that might compromise patient safety.

As more labs in Africa are able to use the same state-of-the-art software systems to streamline and improve day-to-day management, the CDC expects to see more and more labs meet international standards and achieve accredited status as a result. Our work with the ASLM, and SoftTech Health, has been instrumental in guiding our initiatives to take the field of laboratory medicine to the next levelelectronic management of processes, said Carole Moore, Centers for Disease Control and Prevention, with the ultimate outcome being improved diagnostic services and healthier patients.

The African Society for Laboratory Medicine (ASLM) is a Pan-African professional body working with countries to advocate for the critical role and needs of laboratory medicine. ASLM envisions all African nations providing affordable access to quality laboratory services, which make possible effective treatment and prevention of disease and a better life for all people. Visit http://www.aslm.org for more information about ASLM.

Read the original post:

African Society for Laboratory Medicine, CDC, and SoftTech Health Help African Labs Leapfrog over Technical Obstacles

NEW YORK, NY--(Marketwired - Apr 12, 2013) - The Aesthetic Meeting PatientNOW, a leading provider of comprehensive business technology for cosmetic surgery, dermatology, medical spas and aesthetic medical practices, and Modernizing Medicine, the creator of the Electronic Medical Assistant (EMA), a cloud-based specialty-specific electronic medical record (EMR) system, announced today a strategic alliance to offer plastic surgery and cosmetic surgery practices best-in-class solutions for practice management and electronic medical records.

PatientNOW offers a complete software platform for the modern aesthetic medical practice. PatientNOW is a leading edge software developer, meeting the specific needs of aesthetic medicine. From the company's inception, a customer centric focus has resulted in a comprehensive software solution designed by plastic surgeons to meet their unique business requirements. PatientNOW features PAR - Patient Acquisition and Retention, Patient Portal, Photo Management, Inventory Management, Point of Sale and Certified EMR/Practice Management.

"Going in to 2013, we want our customers to be able to choose the EMR that works best for their practice. Modernizing Medicine's cloud-based, specialty specific EMR offers an intuitive and complementary method for medical record documentation," states Jerry Jacobson, PatientNOW President and co-founder. "We are thrilled about this collaboration, which will offer the market a total office solution that will help practices increase their productivity."

Modernizing Medicine's EMA Plastic Surgery and EMA Cosmetic are cloud-based, touch-based mobile EMR systems designed specifically for plastic and cosmetic surgeons. Using the native iPad app, EMA can be accessed virtually anywhere at anytime. Since no two surgeons practice the same way, Modernizing Medicine built EMA as an adaptive learning system, which adjusts to each surgeon's unique practice style. EMA includes the EMA Interactive Anatomical Atlas, which is a tool that enables surgeons to manipulate an image of the body in a zoomable three-dimensional layered way.

"PatientNOW offers one of the best Practice Management systems on the market today and EMA Plastic Surgery and EMA Cosmetic are certainly top of class for specialty-specific EMRs," said Dan Cane, President and co-founder of Modernizing Medicine, "We're thrilled to be able to make available to our customers very strong and complete EMR and practice management systems that will make their patient encounters and documentation process much easier."

Industry leader and President of Karen Zupko & Associates, Inc., Karen Zupko, commented on the collaboration: "The combination of PatientNOW and Modernizing Medicine gives plastic surgeons a solid platform designed specifically for them."

About PatientNOWPatientNOW is the ONE software solution that provides everything for your plastic surgery practice. From initial contact through delivery of services, PatientNOW tracks and documents every step. Automated patient follow-up, appointments, patient portal, photo management, inventory management, patient survey, quotes, invoices, gift cards, birthday reminders and procedure reminders. Increase your revenue and run your office more efficiently.

About Modernizing MedicineModernizing Medicine is delivering the next generation of electronic medical records (EMR) technology for the healthcare industry. Our product, Electronic Medical Assistant (EMA), is a cloud-based specialty-specific EMR with a massive library of built-in medical content, designed to save physicians time. Available as a native iPad application or from any web-enabled Mac or PC, EMA adapts to each provider's unique style of practice and is designed to interface with hundreds of different practice management systems. Today, Modernizing Medicine provides specialty-specific offerings for the dermatology, ophthalmology, optometry, orthopedics, plastic surgery and cosmetic markets, and to more than 800 physician practices across the country. In 2013 Modernizing Medicine was listed at No. 47 on FORBES annual ranking of America's Most Promising Companies.

Read the original here:

PatientNOW and Modernizing Medicine Join Forces to Offer Plastic and Cosmetic Surgery Practices Best-in-Class ...

BOCA RATON, FL--(Marketwired - Apr 11, 2013) - Modernizing Medicine, the creator of the Electronic Medical Assistant (EMA), a cloud-based, specialty-specific, electronic health records (EHR) system, announced today that EMA Dermatology had the highest number of dermatologists successfully attest for Meaningful Use among dermatology specific EHR systems for the 2012 attestation year. Based on numbers from the Office of the National Coordinator for Health Information Technology (ONC), as of January 2013, a total of 362 dermatologists successfully attested using EMA Dermatology, Modernizing Medicine's CCHIT Certified dermatology specific EHR system.

The ONC, along with the Center for Medicare and Medicaid Services (CMS), recently compiled a list of Electronic Health Record (EHR) systems used for the attestation of Meaningful Use under the CMS Medicare and Medicaid EHR Incentive Programs. These programs provide a financial incentive for physicians that demonstrate they are "meaningfully using" certified EHR technology by meeting thresholds for certain objectives established by CMS. For physicians who want to attest for Meaningful Use in 2013 and earn their incentive payments, now is the time to implement an EHR system.

"EMA, which received CCHIT certification in February 2012, did not have any attestations prior to August 2012," said Michael Sherling, MD, Chief Medical Officer and co-founder of Modernizing Medicine. "For successful attestations using EMA from August 2012 to December 2012, an estimated $6.5 million in Meaningful Use incentive dollars will be distributed. We're thrilled to have helped those physicians earn their well-deserved dollars and honored to have them as customers."

"Our five-physician practice attested for Meaningful Use in 2012," said Dr. Jonathan Weiss, a dermatologist with Gwinnett Dermatology in Snellville, Georgia. "By doing our documentation with EMA Dermatology, it was easy for us to attain it. The system kept track of the parameters, and it turned out to be a simple process. Any physician who attests for the first time in 2013 can earn a $15,000 rebate from the government. As long as they learn and follow the guidelines, they should be able to easily obtain it with EMA."

Many physicians using Modernizing Medicine's other specialty-specific EHR systems, including EMA Ophthalmology and EMA Optometry, have also successfully attested for Meaningful Use. Providers must demonstrate Meaningful Use every year to receive incentive payments, and the sooner physicians attest in 2013 the sooner CMS will provide payment. For more information visit http://www.healthit.gov.

Since launching in 2010, Modernizing Medicine has expanded to save over 2,100 providers' time and money with EMA, including over 14% of the dermatology market. For more information please visit http://www.modmed.com.

About Modernizing MedicineModernizing Medicine is delivering the next generation of electronic health records (EHR) technology for the healthcare industry. Our product, Electronic Medical Assistant (EMA), is a cloud-based specialty-specific EHR with a massive library of built-in medical content, designed to save physicians time. Available as a native iPad application or from any web-enabled Mac or PC, EMA adapts to each provider's unique style of practice and is designed to interface with hundreds of different practice management systems. Today, Modernizing Medicine provides specialty-specific offerings for the dermatology, ophthalmology, optometry, orthopedics and plastic surgery markets, and to more than 800 physician practices across the country. In 2013 Modernizing Medicine was listed at No. 47 on FORBES annual ranking of America's Most Promising Companies.

More:

Modernizing Medicine's Electronic Medical Assistant(R) Ranks First Among Specialty Specific EHRs for Dermatologists ...

Touhou 9 PoFV - Sothe vs Dragon Knight (Marisa vs Medicine) hard
Sothe a la Izquierda (Marisa), yo a la derecha (Medicine)

By: ShadeLoki

Go here to read the rest:

Touhou 9 PoFV - Sothe vs Dragon Knight (Marisa vs Medicine) hard - Video

The Record Company performing "Medicine Man" at Toddchella 4/6/13
The Record Company performing "On The Move" at Toddchella 4/6/13. Wrote a little blog entry about it that you can check out here:

By: dklee13

Original post:

The Record Company performing "Medicine Man" at Toddchella 4/6/13 - Video

Uncle Salty (formerly Jokers Wild) #39;Medicine Man #39; video edit
Medicine Man recording from the Uncle Salty debut EP recording sessions. This line up features Gretchie (vox), Terry John (Gtr), Kingy (Bass) and Haddow (D...

By: Gretchie Rock

Go here to read the rest:

Uncle Salty (formerly Jokers Wild) 'Medicine Man' video edit - Video

Daughter - Medicine (The Chainsmokers Remix)
Pandoric! http://facebook.com/Pandoric http://twitter.com/PandMusic The Sound Remedy remix was good, Chainsmokers does it again with their remix of Medicine...

By: PandoraMuslc

Read the rest here:

Daughter - Medicine (The Chainsmokers Remix) - Video

New Delhi, April 10 (IANS) As part of an initiative to promote traditional Indian systems of medicine abroad, the health ministry has signed agreements and set up research facilities to collaborate with international universities, an official said.

The department of AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy) has been making efforts to promote Indian systems of medicine abroad, a health ministry official said Wednesday.

Among initiatives taken is the setting up of the Centre for Research in Indian System of Medicine (CRISM) under the National Centre for Natural Products Research (NCNPR), University of Mississippi, US, to facilitate collaborative research and disseminate information on Ayurveda, Siddha and Unani medicines.

The department also signed a Memorandum of Understanding (MoU) with the Institute for Social Medicine, Epidemiology and Health Economics, Charite University, Berlin (Germany), to conduct a collaborative research on effectiveness and safety of Ayurveda as a treatment system.

An Indo-US interactive meet was organised on AYUSH research to explore the feasibility to conduct joint Indo-US Ayurveda research and to facilitate Ayurveda's entry into mainstream US medicine, the official added.

Apart from this, the health minister of Malaysia visited the AYUSH department and discussed various issues pertaining to cooperation on traditional systems of medicine, the official said.

Go here to read the rest:

Traditional Indian systems of medicine to be promoted abroad

NEW YORK, April 10, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to

http://www.reportlinker.com/p01158259/European-Nuclear-Medicine-/-Radiopharmaceuticals-Market-%5BSPECT/PET-Radioisotopes-Technetium-F-18%5D-%5BBeta/Alpha-Radiation-Therapy-I131-Y-90%5D-%5BApplications-Cancer/Oncology-Cardiac%5D--Stable-Isotopes-Deuterium-C-13---Global-Trends--Forecast-to.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017]

The European radioisotopes market was valued at $1.1 billion in 2012 and is poised to reach $1.6 billion in 2017 at a CAGR of 6.8%.

A study conducted by Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, and other developed regions between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 and OSIRIS in France in 2018 is, however, a major threat for manufacturers.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects, radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

Germany is the largest consumer market for radiopharmaceuticals in the Europe. There are only 5 major reactors in the world and most of the countries are completely dependent on the productions from those reactors. A few countries such as Poland, Australia, Argentina, and South Africa have started producing Tc-99m at their own reactors in a small scale. Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Covidien, Plc (Ireland), GE Healthcare (U.K.), IBA Group (Belgium), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Siemens Healthcare (PETNET) (Germany).

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.) and Isotec (Sigma Aldrich) (U.S.) - in 2012; they jointly contributed more than 50% to the European revenue.

Scope of the Report

Link:

European Nuclear Medicine / Radiopharmaceuticals Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha ...

PRINCETON, N.J.--(BUSINESS WIRE)--

The Bristol-Myers Squibb Foundation and Morehouse School of Medicine (MSM) today jointly announced the creation of the Morehouse School of Medicine/Bristol-Myers Squibb Foundation Partnership for Equity in Diabetes. The partnership will be based at MSMs National Center for Primary Care (NCPC) in Atlanta.

The partnership, which is funded through a five-year, $2.1 million grant from the Foundation, will share successful models and best practices emerging from the Foundations Together on Diabetes initiative and other demonstration projects with the broader U.S. diabetes, community health, public health and primary care practice communities. To date, Together on Diabetes has provided $44.4 million in funding to grantees that are developing, implementing and evaluating community-based care and support projects in and with more than 55 heavily affected communities across the U.S.

Given the devastating impact of diabetes on minorities, the elderly and the poor, there is great urgency to both figure out what works and to share and scale those solutions, said John L. Damonti, president, Bristol-Myers Squibb Foundation. We are fortunate to partner in this work with Morehouse School of Medicine, which is a constant and transformative force in creating health equity in the United States.

Through this grant and the formation of the Partnership for Equity in Diabetes, we have a strategic opportunity to celebrate what is really working in diverse communities across the country, to share their lessons learned and to engage new communities in working together to achieve more optimal diabetes health outcomes for all, said George Rust, Professor of Family Medicine and Director, NCPC, Morehouse School of Medicine.

Announcement of the partnership comes during National Minority Health Month, which is a call to action and unity in the effort to reduce health disparities. Type 2 diabetes is a serious public health problem in the U.S. that places a disproportionately higher disease burden on minority populations. Approximately 18.7 percent of African Americans and 11.8 percent of Hispanic/Latino Americans over age 20 live with the disease compared with 8.3 percent of the total U.S. population. Compounding these statistics, minority populations also face disparities in access to services and supports needed for successful and sustained control of their diabetes.

The Bristol-Myers Squibb Foundation launched Together on Diabetes in the United States in November 2010. The five-year, $100 million U.S. arm of the initiative targets adult populations disproportionately affected by type 2 diabetes and focuses on improving their health outcomes by strengthening patient self-management education, cultivating community-based supportive services and promoting broad-based community mobilization.

NCPC is the only congressionally sanctioned academic research, training and resource center focused on promoting excellence in community-oriented primary care and optimal health outcomes for all Americans, with a special focus on serving underserved communities.

Through this partnership, NCPC will capture, spread and replicate successes drawn from Together on Diabetes grantees and other demonstration and quality improvement projects through three core activities:

You can learn more about Together on Diabetes at http://www.TogetherOnDiabetes.com. To view an interactive map showing the location and project details of the Together on Diabetes project sites in the U.S., go to http://www.bms.com/togetherondiabetes/partners/Pages/partners-map.aspx.

More:

Bristol-Myers Squibb Foundation, Morehouse School of Medicine Partner to Spread Lessons from Together on Diabetes™ ...

DALLAS, April 10, 2013 /PRNewswire/ --

The"North American Nuclear Medicine/Radiopharmaceuticals Market& Stable Isotopes [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13)-Forecast to 2017"analyzes and studies the major market drivers, restraints, and opportunities in North America, Latin America, Europe, Asia, and Rest of the World.

Browse

http://www.marketsandmarkets.com/Market-Reports/north-american-nuclear-medicine-radiopharmaceuticals-market-1108.html

Early buyers will receive 10% customization on this report.

This report studies the North American nuclear medicine market over the forecast period 2012-2017.

The North American radiopharmaceutical market was valued at $1.9 billion in 2012 and is poised to reach $2.7 billion by 2017 at a CAGR of 7.2%. It is estimated that Tc-99m diagnostic procedures are expected to increase by more than 15% in mature markets such as North America, between 2010 and 2030, however shortage of Mo-99/Tc-99m has been a threat to this industry. The scheduled shutdown of the NRU reactor in 2016 is a major risk for manufacturers in the near future. Companies have increased the production of thallium to meet the shortage, as it is the most commonly used substitute for technetium-99 in cardiac-stress tests, conducted to evaluate the functioning of coronary arteries. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications.

Increasing use of SPECT and PET scans, technical advancements in equipment and other factors such as rising awareness of radiopharmaceuticals among physicians, alpha radio immunotherapy based targeted cancer treatment, and ready availability of north american nuclear medicine / radiopharmaceutical market from cyclotrons have driven the market. High cost of devices using radioisotopes, short half-life, lack of good manufacturing practices, and stringent regulatory approvals are major hurdles to growth of the market.

North America is the dominant market for diagnostic radioisotopes. The U.S. is the largest consumer market for radiopharmaceuticals, while Canada is one of the largest producers of Tc-99m.

Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Triad Isotopes, Inc. (U.S.), Cardinal Health dominated with more than 40% share in 2012.

View post:

North American Nuclear Medicine / Radiopharmaceutical Market Worth $5.55 Billion by 2017

WALTHAM, Mass., April 10, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, welcomed the announcement today that Abbott has obtained a CE Mark for the Galectin-3 assay run on the ARCHITECT immunochemistry platform.

The launch of the ARCHITECT Galectin-3 test under CE Mark will further expand the availability of galectin-3 testing in several European countries, pending country registration. BG Medicine is partnering with four diagnostic instrument manufacturers to commercialize automated versions of the BGM Galectin-3 test.

"The launch of the ARCHITECT Galectin-3 test under CE Mark is another important step in our commercial strategy. We are very pleased with the progress made by our partner Abbott, a worldwide leader in in vitro diagnostics, to expand the use of galectin-3 testing in heart failure patients," said Eric Bouvier, President and Chief Executive Officer of BG Medicine. The announcement will strengthen our ability to drive the growth of galectin-3 testing throughout the world."

"Galectin-3 is a powerful indicator of prognosis and risk for readmission in heart failure. Having a rapid turn-around galectin-3 result means heart failure patients at high-risk for such adverse events can be more readily identified," said Stefan Anker MD, PhD and President of the Heart Failure Association of the European Society of Cardiology. "Given the rise in heart failure, it is critical we introduce new tools that aid fast clinical decision making processes and provide options to explore new interventions."

In addition to Abbott, BG Medicine is partnering with Alere Inc., bioMerieux SA, and Siemens Healthcare Diagnostics Inc. to supply automated versions of its galectin-3 test to key segments of the market. Earlier this year, bioMerieux SA launched the test in Europe and in certain other territories that recognize the CE Mark.

About Galectin-3 testing

Galectin-3 has been implicated in a variety of biological processes important in the development and progression of heart failure. Higher levels of galectin-3 are associated with a more aggressive form of heart failure, which may make identification of high-risk patients using galectin-3 testing an important part of patient care. Galectin-3 testing may be useful in helping physicians determine which patients are at higher risk of death or hospitalization, including 30-day readmission.

About BG Medicine, Inc.

BG Medicine, Inc. (BGMD) is a diagnostics company focused on the development and commercialization of novel cardiovascular tests to address significant unmet medical needs, improve patient outcomes and reduce healthcare costs. The Company has two products: the BGM Galectin-3(R) test for use in patients with chronic heart failure is available in the United States and Europe; and the CardioSCORE(TM) test for the risk prediction of major cardiovascular events is expected to be launched in Europe in the first half of 2013. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit http://www.bg-medicine.com and http://www.galectin-3.com.

The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352

View original post here:

BG Medicine Welcomes CE Mark for Galectin-3 Test

Married to Medicine Season 1 Ep 1 2 Review
Married 2 Medicine Review Season 1 Episodes 1 2 Review. Be sure to rate, comment, Subscribe and tell a friend or two... Twitter: @sayShawnBradley @guysatbr...

By: sayShawnBradley

See the article here:

Married to Medicine Season 1 Ep 1

Wagon Wheel by Darius Rucker/Old Crowe Medicine Show (Cover)

By: somethingdifferent33

Read the original here:

Wagon Wheel by Darius Rucker/Old Crowe Medicine Show (Cover) - Video

Medicine Today in Armenian: Glaucoma, Cataract and Macular Degeneration
Medicine Today Tuesday, April 2, 2013 Glaucoma, Cataract and Macular Degeneration Guest: Mireille Hamparian, M.D., Board Certified Hosted by Dr. Sahag Arslanian.

By: MedicineTodayShow

Original post:

Medicine Today in Armenian: Glaucoma, Cataract and Macular Degeneration - Video

Guru - Medicine
______\ I do not owned any rights. //______. Uploaded For Listening Purposes. Jazzmatazz, Vol. 2: The New Reality St...

By: OutOfThisDemension

Follow this link:

Guru - Medicine - Video

Tesla - Edison #39;s Medicine LIVE @ Shout It Out Loud Festival Duisburg 05.04.2013

By: tommyconcert

Here is the original post:

Tesla - Edison's Medicine LIVE @ Shout It Out Loud Festival Duisburg 05.04.2013 - Video